Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.9433
- Book/Share 32.6431
- PB 6.3248
- Debt/Equity 0.0806
- CurrentRatio 1.0736
- ROIC 0.1293
- MktCap 497423066759.0
- FreeCF/Share 7.8498
- PFCF 26.0923
- PE 19.9613
- Debt/Assets 0.0331
- DivYield 0.0249
- ROE 0.3269
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | JNJ | Scotiabank | -- | Sector Outperform | -- | $230 | Nov. 13, 2025 |
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades
Published: December 01, 2025 by: Seeking Alpha
Sentiment: Positive
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. We initiated a position in this customer relationship management software company because it enjoys a dominant market share and a wide competitive moat. We exited our position in nVent. It rallied on the prospect of increasing data center demand, pushing the stock above what we viewed as its fair value.
Read More
Time to Shore Up Your Personal Portfolio With These 3 Bullet-Proof Blue-Chip Stocks
Published: December 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
There are a number of valid reasons why many investors may be souring on the ability of equity markets to continue to rise at a 20%+ rate in the years to come.
Read More
JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
Read More
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Read More
3 Smart Defensive Stocks for an Uneasy Market
Published: November 18, 2025 by: MarketBeat
Sentiment: Positive
At one point in early November, the Dow Jones Industrial Average (DJIA) briefly topped 48,000 for the first time ever. At different times in 2025, the NASDAQ and S&P 500 have made new all-time highs (ATHs).
Read More
Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
Published: November 17, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedented year of strategic exits and reinforcing the firm's disciplined, science-first approach to company building and investing. Earlier today, Halda Therapeutics announced its acquisition by Johnson & Johnson (NYSE: JNJ) for $3.05 billion, marking a historic moment for the Vida III portfolio. Hald.
Read More
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson ( JNJ ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM EST Company Participants Candice Long - Worldwide Vice President of Immunology David Lee - Global Therapeutic Area Head, Immunology for Janssen Pharmaceutical Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Presentation Alexandria Hammond Wolfe Research, LLC Good morning, everybody. My name is Alex Hammond, and I'm the biopharma analyst here at Wolfe.
Read More
Johnson & Johnson strengthens oncology portfolio with $3B Halda Therapeutics acquisition
Published: November 17, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ) announced that it has entered into a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotechnology company focused on developing targeted oral therapies for solid tumors, for $3.05 billion in cash. Halda's lead candidate, HLD-0915, is a once-daily oral therapy for prostate cancer that received FDA fast track designation in August 2025 following positive preliminary data from Phase 1/2 trials.
Read More
Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment
Published: November 17, 2025 by: Investors Business Daily
Sentiment: Neutral
Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Why Is Johnson & Johnson (JNJ) Up 1.7% Since Last Earnings Report?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson ( JNJ ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Menziuso Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good morning, everyone.
Read More
Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson ( JNJ ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM EST Company Participants Sarah Brennan Mark Wildgust Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Presentation Vamil Divan Guggenheim Securities, LLC, Research Division Okay. I think we're ready to get going here.
Read More
Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG study in which pediatric patients receiving treatment with IMAAVY™ demonstrated 72 weeks of sustained reduction in immunoglobulin G (IgG), sustained disease control and no new safety concerns IMAAVY™ is the only FcRn blocker for anti-AChR and anti-MuSK antibody positive adult and pediatric gMG patients aged 12 and older that has demonstrated sustained disease control SPRING HOUSE, Pa. , Oct. 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced …
Read More
J&J Stock Can Fall
Published: October 28, 2025 by: Forbes
Sentiment: Negative
Johnson & Johnson (JNJ) is currently encountering challenges. Even the largest corporations are not invulnerable.
Read More
Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
Published: October 28, 2025 by: Reuters
Sentiment: Negative
The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit hyperactivity disorder.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
Read More
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
Published: October 24, 2025 by: PRNewsWire
Sentiment: Neutral
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus placebo Critical patient-reported SjD symptoms including dryness, pain and fatigue trended towards greater improvement in the nipocalimab-treated group compared to placebo-treated patients Nipocalimab is the only investigational treatment to be granted Breakthrough Therapy Designation (BTD) by U.S. FDA for the treatment of adults living with moderate-to-severe SjD, and the Phase 3 DAFFODIL study is currently enrolling patients SPRING HOUSE, Pa. …
Read More
I have invested in dividends for 20 years. These stocks are my top dividend compounders of all time
Published: October 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
In the world of investing, dividends have long been a popular way to earn income alongside growth opportunities with stocks.
Read More
Johnson & Johnson Stock To $134?
Published: October 22, 2025 by: Forbes
Sentiment: Negative
Our machine-driven multifactor analysis suggests it may be time to sell JNJ stock, as we hold a pessimistic outlook with a potential target price of $134. The company's Moderate operating performance and financial health, combined with its High valuation, make the stock appear Unattractive.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys
Published: October 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.
Read More
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.
Read More
J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100